The innovative clinical-stage immunotherapy company highlighted in today’s article has a slew of bullish indicators, suggesting it’s gearing up for a surge – and the author outlines one trade idea for this stock that offers upside potential of 41% to 124% in the next four to six months. For the stock in question, the bullish indicators and the details of the recommended trade, CLICK HERE.